Home >> Top News >> IVD adoption could save NHS nearly $8 billion

IVD adoption could save NHS nearly $8 billion

Print Friendly, PDF & Email

June 20, 2018—Research commissioned by Innovate UK and the British In Vitro Diagnostics Association indicated that the UK’s National Health Service could save more than £6.9 billion ($8 billion) in five years if it adopted three in vitro diagnostic tests.

The report, written by Aquarius Population Health, said that tests for heart attack, preeclampsia, and inflammatory bowel disease would benefit patients by “reducing unnecessary procedures and medication while delivering significant NHS savings,” according to a joint release from Innovate UK and BIVDA. The report notes that experts have forecast a shortfall in NHS funding of “at least £22 billion” [$25.5 billion] by 2022 and calls on health care leaders and policymakers to reassess how these tests and other diagnostic technologies could be better deployed within the NHS.

“There are so many innovative diagnostic tests on the market and in development. It’s important for all stakeholders that we take every opportunity to rapidly adopt tests which show cost savings and benefit to patients,” Kath Mackay, PhD, Innovate UK interim director for Ageing Society, Health & Nutrition, said in the release.

More top news

x

Check Also

Molecular ‘bucket list’ for renal cancer

September 2018—Leo Tolstoy is not listed as a coauthor on the most recent iteration of The Cancer Genome Atlas on renal cell carcinoma, which focuses on molecular characterization of RCC. But the topic is as rich and complex as a Russian novel, and the authors’ approach is so comprehensive, it’s tempting to picture them at least holding forth at a certain soirée in Saint Petersburg (minus the after-party drunkenness and the bit with a bear, of course). The project may not be as sprawling as War and Peace, which marches 559 characters, speaking two languages, over four volumes, 15 parts, and 333 chapters. It’s a heroic effort nonetheless. There is much to keep track of in renal cell carcinoma, both generally and in this latest document, which evaluates 843 RCCs from three major histologic subtypes, including 488 clear cell RCC, 274 papillary RCC, and 81 chromophobe RCC.

X